{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:00:22Z","timestamp":1793833222600,"version":"4.6.1"},"reference-count":92,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>B-cell maturation antigen (BCMA)-targeted therapies including both chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs), have revolutionized the treatment landscape for relapsed\/refractory multiple myeloma (MM), offering both deep and durable responses, even in heavily pretreated patients. Despite these advances, most patients ultimately experience relapse. This is likely related to the development of resistance mechanisms that limit the long-term efficacy and durability of BCMA-targeted approaches. In this review, we examine the current landscape of BCMA-directed therapies, including Idecabtagene Vileucel, Ciltacabtagene Autoleucel, Teclistamab, and Elranatamab and explore the multifactorial mechanisms driving resistance. These mechanisms include tumor-intrinsic factors, host-related and tumor-extrinsic factors, and factors related to the tumor-microenvironment itself. We outline emerging strategies to overcome resistance, such as dual-targeting therapies, \u03b3-secretase inhibitors, immune-checkpoint blockade, armored CAR T constructs, and novel combination regimens. Additionally, we discuss the role of therapy sequencing, emphasizing how prior exposure to BsAbs or CAR T-cell therapies may influence the efficacy of subsequent treatments. A deeper understanding of resistance biology, supported by integrated immune and genomic profiling, is essential to optimizing therapeutic durability and ultimately improve patient outcomes for patients with MM.<\/jats:p>","DOI":"10.3390\/cells14141077","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:45:52Z","timestamp":1752572752000},"page":"1077","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma"],"prefix":"10.3390","volume":"14","author":[{"given":"Brandon","family":"Tedder","sequence":"first","affiliation":[{"name":"Advocate Health Levine Cancer Institute, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Advocate Health Levine Cancer Institute, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"Laabi","year":"1992","journal-title":"EMBO J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V81.2.454.454","article-title":"Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes","volume":"81","author":"Kozlow","year":"1993","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/cbf.3169","article-title":"Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways","volume":"34","author":"Shen","year":"2016","journal-title":"Cell Biochem. Funct."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3892\/ol.2017.6528","article-title":"Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance","volume":"14","author":"Pan","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","article-title":"BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma","volume":"93","author":"Bolkun","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: Therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","unstructured":"Tedder, B. (2025, June 29). Available online: https:\/\/BioRender.com\/a2ezh17."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1","volume":"140","author":"Casneuf","year":"2022","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","article-title":"Monoallelic deletion of BCMA is a frequent feature in multiple myeloma","volume":"7","author":"Samur","year":"2023","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12964-024-01894-2","article-title":"Trogocytosis in CAR immune cell therapy: A key mechanism of tumor immune escape","volume":"22","author":"Chen","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","article-title":"Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape","volume":"8","author":"Zhai","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70283","DOI":"10.1002\/cam4.70283","article-title":"Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouze","year":"2024","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-142426","article-title":"Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy","volume":"136","author":"Finney","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mehta, P.H., Fiorenza, S., Koldej, R.M., Jaworowski, A., Ritchie, D.S., and Quinn, K.M. (2021). T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.780442"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood-2023-173550","article-title":"Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1\/2 MajesTEC-1 Study of Patients with Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., and Tu, S. (2019). Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02664"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101256","DOI":"10.1016\/j.blre.2025.101256","article-title":"Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma","volume":"70","author":"Yue","year":"2025","journal-title":"Blood Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2023-174941","article-title":"Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2022-159353","article-title":"ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens","volume":"140","author":"Pihlgren","year":"2022","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: A phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-21-0062","article-title":"Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses","volume":"9","author":"Yang","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"gamma-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Offner, F., Decaux, O., Hulin, C., Anguille, S., Sophie Michallet, A., Costa, L., Touzeau, C., Boyd, K., Vishwamitra, D., and Guo, Y. (2023). S194: Teclistamab (Tec) + Nirogacestat (Niro) in Relapsed\/Refractory Multiple Myeloma (Rrmm): The Phase 1b Majestec-2 Study. HemaSphere, 7.","DOI":"10.1097\/01.HS9.0000967688.12579.64"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"gamma-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: A phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic Antitumor Activity of Alnuctamab (ALNUC.; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2021-152160","article-title":"Preclinical Assessment of CDR101\u2014A BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy","volume":"138","author":"Vrohlings","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.1182\/blood-2022-157011","article-title":"CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","volume":"140","author":"Hutchings","year":"2022","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/bloodadvances.2024015285","article-title":"Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma","volume":"9","author":"Waldschmidt","year":"2025","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Rupp, L.J., Schumann, K., Roybal, K.T., Gate, R.E., Ye, C.J., Lim, W.A., and Marson, A. (2017). CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-00462-8"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Alabanza, L.M., Xiong, Y., Vu, B., Webster, B., Wu, D., Hu, P., Zhu, Z., Dropulic, B., Dash, P., and Schneider, D. (2022). Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-beta. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.832645"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Battram, A.M., Bachiller, M., Lopez, V., Fernandez de Larrea, C., Urbano-Ispizua, A., and Martin-Antonio, B. (2021). IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers, 13.","DOI":"10.3390\/cancers13143534"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omtm.2021.12.005","article-title":"Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages","volume":"24","author":"Joedicke","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_88","first-page":"1514","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience","volume":"109","author":"Hashmi","year":"2024","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","article-title":"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma","volume":"14","author":"Chakraborty","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Nath","year":"2023","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/14\/1077\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:48Z","timestamp":1760033388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/14\/1077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":92,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cells14141077"],"URL":"https:\/\/doi.org\/10.3390\/cells14141077","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}